Feature Article

Developing and Commercialising Companion Diagnostics


Posted in IVD by Camilla Andersson on September 27, 2011

An overview of the technology and key success factors of companion diagnostics, including case studies highlighting
the challenges of developing viable products.


Companion diagnostics (CDx)—tests used to ensure that prescribed drugs will be safe and effective for particular patients—have been hailed as driving an impending revolution in medicine. However, most CDx developers must overcome a variety of hurdles if they are to achieve developmental and commercial success in a complex and rapidly changing medical landscape.

In this article, we provide an overview of major current and next-generation CDx and consider the technological requirements for their successful development and commercialisation. Case studies of the well-known CDx products Her2/Neu and Trofile are presented to illustrate the challenges faced by CDx developers. Our focus is on in vitro diagnostic tests and technologies/methodologies for companion diagnostics employed in clinical settings to enhance safety, efficacy and responses to therapeutic treatment. We do not address technologies used in discovering or identifying companion diagnostic biomarkers or CDx technologies employed for drug discovery.

Current and emerging technologies in companion diagnostics (CDx)
Diagnostics developers often must choose among many methods for detecting biomarkers. Deciding which technology to use depends on the biomarker’s characteristics, the measurements required and how the diagnostic will be used. For example, in oncology, when the target gene can be mutated in many different ways and if clinical samples contain a high fraction of neoplastic cells, direct or indirect sequencing methods might be most appropriate in order to detect all possible mutations. By contrast, if there are only one or a few known mutations, polymerase chain reaction (PCR) is generally easier and cheaper.

The pros and cons of each technology must be carefully evaluated in order to determine which will best show whether a specific prescription drug will be safe and effective for a specific patient.

Emerging technologies
Next-generation technologies are expanding the applicability of sequencing. Methods now in the pipeline will offer higher throughput and lower price per base compared with traditional sequencing and can perform millions of reactions concurrently. Advances in data processing and storage are making these technologies more amenable for use in clinical diagnostics.

For example, single molecule sequencing enables analysis of genomic information from small amounts of DNA without the need for amplification, thus enabling data generation in a few hours instead of the days or weeks required for traditional sequencing. Greater efficiency is likely to be a key driver in the adoption of next-generation sequencing technologies for companion diagnostics.

Other technology advances, such as quantitative histopathology, quantum dots (QDots) and digital pathology will propel older protein detection technologies such as IHC to the forefront of CDx. 

  • Quantitative histopathology technology provides for the measurement and localisation of protein biomarkers in tissue. An automated fluorescence-based imaging platform is used to identify and quantify tissue biomarkers in either a high-throughput tissue microarray format or in tissue slices. 
  • QDots linked to antibodies and applied to tissue sections can be designed to produce many discrete wavelengths of fluorescent light with minimal spectral overlap, thus achieving a high order of multiplexing while preserving an ability to visualise cell structure and tumour architecture. 
  • Digital pathology will enable better standardisation and quality control in the interpretation of immunohistochemistry (IHC), thus minimising pathologists’ tendency to falsely overcall samples and alleviating the need for additional tests or methods to ensure quality.

Key success factors for a companion diagnostic test
In order to successfully develop and market CDx, companies must address a variety of key factors that will encourage routine, widespread use of their products.

Successful development requires availability of material suitable for testing; biomarkers predictive of a therapeutic response; and accurate, cost-effective techniques for detecting the biomarkers. As mentioned above, selection of the appropriate technology depends on the type of biomarker to be detected.

Adoption and commercial success of a CDx technology require, among other attributes: flexibility in handling clinically relevant body fluids and tissue biopsy samples; cost-effectiveness and scalability in relation to clinical demand; accuracy, reliability and efficient turnaround time; and, the ability to multiplex efficiently in light of patient-to-patient heterogeneity and the limited utility of single biomarkers.

The business ramifications of hitting key success factors
For even the most successful CDx companies, providing tools to enhance the use of therapeutics is no simple matter; many companies struggle to meet key developmental and commercial success factors. Case studies of two well-known CDx, HER2/Neu (developed by a variety of suppliers including Dako and Abbott and sold along with Genentech’s Herceptin) and Trofile, developed by Monogram Bioscience (sold along with Pfizer’s Selzentry), illustrate how new knowledge, changing technologies and the need for scalability of technology influence effectiveness, widespread CDx use and diagnostic and therapeutic sales.

Case study: HER2/Neu-Herceptin1, 2, 3, 4
Herceptin treats HER2-overexpressing metastatic breast cancer. When the drug was still in clinical trials, an IHC test, HercepTest, was developed and approved essentially simultaneously with Herceptin in order to identify populations that would best respond to the drug. Once Herceptin was approved, studies showed that, because IHC is not quantitative and there was high variability in reagents, test results were often inaccurate and that different labs had different rules for classifying positive and negative HER2 status. Moreover, there was heavy discordance when the results were borderline (that is, not strongly HER2-positive or HER2-negative). In some cases, tissue from one area of a breast cancer tested HER2-positive and tissue from a different area of the cancer tested HER2-negative. This was largely caused by high variability in IHC reagents, protocols and laboratory interpretations. As a result, Genentech and clinical laboratories had to rely on the evolution of more reliable but indirect measurements such as fluorescence in situ hybridisation (FISH). But FISH, which quantitatively measures gene copy number, is expensive and requires additional equipment and training that most laboratories lack. As a result most laboratories still use only IHC.

Because inaccurate HER2 test results may lead to inadequate care, in order to prevent false negatives, some laboratories that primarily use IHC retest with FISH when IHC results are unclear or borderline. However, this dual strategy fails to measure the activity of HER2 pathway directly and provides inaccurate results in 20% of cases.4 The optimum CDx for HER2 would directly measure the activity state of the HER2 protein. Furthermore, it should require minimal expertise to interpret the results. None of the current tests fulfill these criteria.

New technologies such as Monogram’s (now Labcorp) proximity assay, and Ventana’s (now Roche) recently approved dual in situ hybridisation (ISH) assay, may be important in making HER2 testing more reliable. Standardised digital IHC also may help reduce variability among laboratories. The Ventana assay allows visual counting of the number of HER2 gene copies on chromosome 17 under a microscope. Based on a staining system that colours chromosome 17 red and the HER2 gene black, it is easier to use than a FISH test. Additionally, the assay makes the HER2 and chromosome 17 copies visible for longer periods. However, further investigation and validation will be required to determine whether such technologies accurately measure HER2 amplification. Given the high cost of Herceptin, its side effects, and the life-threatening nature of the disease, developing more accurate CDx and evaluating them in well-designed clinical trials will be critical. Until this happens, erroneous treatment of breast cancer patients will continue and result in increased healthcare costs.

Case study: Trofile-Selzentry
Selzentry is an antiviral medication used with other medications to treat HIV patients. Classified as a CCR5 co-receptor antagonist, it works by slowing the spread of HIV in the body. A tropism test is a blood test that reveals how HIV enters T-cells and which receptors the virus uses. Tropism testing is necessary if Selzentry is to be included in an antiviral regimen. Selzentry is effective against CCR5-using HIV only. Tropism testing should be done to help determine if Selzentry is going to work.

Monogram Biosciences’ Trofile assay is a complex co-receptor tropism test that predicts response to Selzentry. Trofile is an unusual case because the pharmaceutical company Pfizer codeveloped the assay with the developer, Monogram Biosciences (now Labcorp). Pfizer invested US$25 million in Monogram Biosciences to develop the Trofile test, and currently markets the test with Selzentry. Monogram was the sole provider of the test, partly because the test required specialised expertise not available in routine clinical laboratories.

However, the test’s lengthy 18-day turnaround time inhibited widespread adoption. As test volumes increased and worldwide roll out of Selzentry began, Pfizer and Monogram faced both scale-up and adoption problems and third-party payers were slow in agreeing to reimburse for the test, further slowing adoption. As a result, despite co-development and a strong Rx-Dx partnership, Selzentry sales fell short of expectations.

In conclusion, many CDx technologies are available today and exciting new technologies such as next-generation sequencing are on the horizon. To create effective tests, companion diagnostics developers must carefully select technologies based on the characteristics of the particular biomarker and on how the diagnostic will be used. To ensure routine, widespread adoption, they must thoroughly evaluate the pros and cons of the technology and make sure that the key factors of accuracy, reliability, cost effectiveness, turnaround time and scala-bility are consistent with clinical demand.
 

References
1. N. Papadopoulos, K.W. Kinzler, B. Vogelstein, “The role of companion diagnostics in the development and use of mutation-targeted cancer therapies,” Nat Biotechnol., 24, 8, 985-995 (2006).
2. W.H. Koch, “Technology platforms for pharmacogenomic diagnostic assays,” Nat Rev Drug Discov., 3, 9, 749-761 (2004).
3. A.C. Wolff et al., “American Society of
Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer,” J Clin Oncol, 25, 1, 118–145 (2007).
4. College of American Pathologists, HER2 Testing Guidelines, Accessed 23 February 2009.

 

Aruna Rajan
is Senior Associate,
Michael Jacobson
is Manager,
Kerry Xie
is Senior Analyst and
Harry Glorikian*
is Managing Partner at Scientia Advisors
55 Cambridge Parkway, Suite 300E,
Cambridge, MA 02142, USA
tel. +1 617 407 5093
hglorikian@scientiaadv.com
www.scientiaadv.com

* to whom all correspondence should be sent
 

A recent post on the EMDT blog medtechinsider.com recently discussed companion diagonostics and an upcoming UBM Canon tradeshow on clinical diagnostics. Read more in the medtechinsider post Diagnostica Europe 2012.



Find more content on:
No votes yet


Login to post comments

Comment viewing options

Select your preferred way to display the comments and click "Save settings" to activate your changes.

This program comes with over

This program comes with over 140 videos, complete step-by-step plans, personal advice and community support
that has been put together as a unique system to transform your mind and body.

Bar Brothers System Review

home guard home warranty

I want you to thank for your time of this wonderful read!!! I definately enjoy every little bit of it.
home guard home warranty

gl homes warranty

A very awesome blog post. We are really grateful for your blog post. gl homes warranty,home warranty usaa

I recently found many useful

I recently found many useful information in your website especially this blog page. Among the lots of comments on your articles. Thanks for sharing.
queensland lawyers

Every word in this piece of

Every word in this piece of work is very clear and your passion for this topic shines. Please continue your work in this area and I hope to see more from you in the future.
Panasonic CE12PKE

Hi, I find reading this

Hi, I find reading this article a joy. It is extremely helpful and interesting and very much looking forward to reading more of your work..
magnetic messaging system free

cheers for the actual article

cheers for the actual article i have recently been on the lookout with regard to this kind of advice on the net for sum time right now so many thanks
Rebelmouse com

and outsourcing pipette

and outsourcing pipette calibration to laboratories at different elevations are common occurrences in today’s life science community. And all of these tasks can expose pipettes to harsh environments and put data at risk. obat peninggi badan

I really impressed after read

I really impressed after read this because of some quality work and informative thoughts . I just wanna say thanks for the writer and wish you all the best for coming!.

www.rebelmouse.com/edprotocolreviews/

Thanks for taking the time to

Thanks for taking the time to discuss this, I feel strongly about it and love learning more on this topic.
best panic attack solutions

Thanks for sharing this

Thanks for sharing this interesting info, I really appreciate it statusparawhatsapp.com

Thanks for sharing nice

Thanks for sharing nice information with us. i like your post and all you share with us is uptodate and quite informative,
i would like to bookmark the page so i can come here again to read you, as you have done a wonderful job
https://www.youtube.com/watch?v=SSjazV8La-k

Should there be another

Should there be another persuasive post you can share next time, I’ll be surely waiting for it.
padova

I really appreciate this

I really appreciate this wonderful post that you have provided for us. I assure this would be beneficial for most of the people.

chess pieces

Hi there, I found your blog

Hi there, I found your blog via Google while searching for such kinda informative post and your post looks very interesting for me.
sad status

I read this article. I think

I read this article. I think You put a lot of effort to create this article. I appreciate your work προωθηση ιστοσελιδων

I really loved reading your

I really loved reading your blog. It was very well authored and easy to understand. Unlike other blogs I have read which are really not that good.Thanks alot!

online payday loans

You have a good point here!I

You have a good point here!I totally agree with what you have said!!Thanks for sharing your views...hope more people will read this article!!!
symptoms of mesothelioma

This is a great inspiring

This is a great inspiring article.I am pretty much pleased with your good work.You put really very helpful information. Keep it up. Keep blogging. Looking to reading your next post.
peliculas online

I really appreciate the kind

I really appreciate the kind of topics you post here. Thanks for sharing us a great information that is actually helpful. Good day!

obat kuat herbal

I was checking constantly

I was checking constantly this blog and I am impressed! Extremely helpful information specially the last part I care for such info a lot. I was seeking this particular information for a very long time Hemorrhoid No More Review

That is really nice to hear.

That is really nice to hear. thank you for the update and good luck.
http://girlfriendactivationsystem.co/

I was very pleased to find

I was very pleased to find this site.I wanted to thank you for this great read!! I definitely enjoying every little bit of it and I have you bookmarked to check out new stuff you post.
http://numerologyreview.com

Thanks For sharing this

Thanks For sharing this Superb article.I use this Article to show my assignment in college.it is useful For me Great Work.
http://antoniapearceromance.com/

I am happy to find this post

I am happy to find this post very useful for me, as it contains lot of information. I always prefer to read the quality content and this thing I found in you post. Thanks for sharing.
how to attract a girl who has lost interest in you

Interesting and amazing how

Interesting and amazing how your post is! It Is Useful and helpful for me That I like it very much, and I am looking forward to Hearing from your next..
kostenlos

Very useful post. This is my

Very useful post. This is my first time i visit here. I found so many interesting stuff in your blog especially its discussion. Really its great article. Keep it up.
TextYourExBackForum com

I can set up my new idea from

I can set up my new idea from this post. It gives in depth information. Thanks for this valuable information for all,..
what to do when a girl likes you but doesn't want to date

I would love to stop by. But,

I would love to stop by. But, I think it might have to wait until this summer. I did not know that Serlkay had ever expanded its size. I must say that a succesful family owned business in this day and age is a very refreshing sight! As well as this is a very refreshing site!
Tourism in China

Excellent article. Very

Excellent article. Very interesting to read. I really love to read such a nice article. Thanks! keep rocking.
text your ex back

I admit, I have not been on

I admit, I have not been on this web page in a long time... however it was another joy to see It is such an important topic and ignored by so many, even professionals. professionals. I thank you to help making people more aware of possible issues.

http://rebelmouse.com

Every word in this piece of

Every word in this piece of work is very clear and your passion for this topic shines. Please continue your work in this area and I hope to see more from you in the future.
Edward Bass Producer

Thanks for a wonderful share.

Thanks for a wonderful share. Your article has proved your hard work and experience you have got in this field. Brilliant .i love it reading.
revisione e l'anteprima del programma

This type of message always

This type of message always inspiring and I prefer to read quality content, so happy to find good place to many here in the post, the writing is just great, thanks for the post.
private jet charter prices

I just found this blog and

I just found this blog and have high hopes for it to continue. Keep up the great work, its hard to find good ones. I have added to my favorites. Thank You.
https://www.rebelmouse.com/amandaletofibroidsmiracle

https://www.flickr.com/people/buyfacebooklike/

Very informative post! There is a lot of information here that can help any business get started with a successful social networking campaign!
Buy Facebook Likes Cheap

It was wondering if I could

It was wondering if I could use this write-up on my other website, I will link it back to your website though.Great Thanks.
http://www.rebelmouse.com

Wow i can say that this is

Wow i can say that this is another great article as expected of this blog.Bookmarked this site..
www.loveetcetc.com

Thanks for sharing, it was

Thanks for sharing, it was nice to read this article. google sniper 3.0 reviews

https://www.youtube.com/watch?v=juX4jmjdu4s

Hmm… I read blogs on a similar topic, but i never visited your blog. I added it to favorites and i’ll be your constant reader.
buying facebook likes

I have read your article, it

I have read your article, it is very informative and helpful for me.I admire the valuable information you offer in your articles. Thanks for posting it.. dong ho deo tay nu

Thank you very much for this

Thank you very much for this useful article. I like it.
rebelmouse

As you can see from the above

As you can see from the above article, taking for granted the ability to see is something that many of us have always done. But now since you read a good article about eye care, you see the importance of caring for this special part of our body. All it takes is for you to follow the great eye care tips that you just read. buy restore my vision today site

Thanks for posting this info.

Thanks for posting this info. I just want to let you know that I just check out your site and I find it very interesting and informative. I can't wait to read lots of your posts.
does it really work

I'm glad I found this web

I'm glad I found this web site, I couldn't find any knowledge on this matter prior to.Also operate a site and if you are ever interested in doing some visitor writing for me if possible feel free to let me know, im always look for people to check out my web site.
about the book

I would like to thank you for

I would like to thank you for the efforts you have made in writing this article. I am hoping the same best work from you in the future as well. Thanks...
https://www.rebelmouse.com/ultimateherpesprotocolreviews

I really appreciate the kind

I really appreciate the kind of topics you post here. Thanks for sharing us a great information that is actually helpful. Good day!
whitening cream for face

You want to focus on eating

You want to focus on eating enough for you to gain roughly a pound per week. Research ways to bump up your calories, and if increased caloric intake does not improve your mass, you may want to raise the number of calories you are eating again. does somanabolic muscle maximizer really work

Hi! Thanks for the great

Hi! Thanks for the great information you havr provided! You have touched on crucuial points!
https://rebelmouse.com/venusfactorsystemreview

No doubt this is an excellent

No doubt this is an excellent post I got a lot of knowledge after reading good luck. Theme of blog is excellent there is almost everything to read, Brilliant post.
hypotheekwinkel